Merck has announced positive results from its Phase III trial into Keytruda for non-small cell lung cancer.
The KEYNOTE-091 study found that patients who received adjuvant treatment with Keytruda (pembrolizumab) saw a 24% reduced risk of disease recurrence or death, compared to those who were given a placebo. Disease-free survival (DFS) is one of the study’s primary endpoints, alongside improvement in DFS for patients whose tumours express PD-L1.
Merck has announced positive results from its Phase III trial into Keytruda for non-small cell lung cancer.
